New in vivo evidence confirms that tumor-expressed Fas ligand impairs immune responses to cancer by inducing apoptosis of anti ... of the intraperitoneal NK cell population 6.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

The research team, led by Professor Tu Wenwei (second right) and Professor Wang Weiping (second left), has made a ...

Cellistic has launched the Echo-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases.

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

As well as a chimeric antigen receptor (CAR), ONK adds a tumor necrosis factor (TNF)–related apoptosis ligand (TRAIL) variant to create dual-targeted CAR-NK cells (Fig. 1). The selection of ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...